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KRAS is one of the most commonly mutated onco-
genes in human cancer. Mutant KRAS aberrantly reg-
ulatesmetabolic networks. However, the contribution
of cellularmetabolism tomutant KRAS tumorigenesis
is not completely understood. We report that mutant
KRAS regulates intracellular fatty acid metabolism
through Acyl-coenzyme A (CoA) synthetase long-
chain family member 3 (ACSL3), which converts fatty
acids into fatty Acyl-CoA esters, the substrates for
lipid synthesis and b-oxidation. ACSL3 suppression
is associated with depletion of cellular ATP and
causes the death of lung cancer cells. Furthermore,
mutant KRASpromotes the cellular uptake, retention,
accumulation, and b-oxidation of fatty acids in lung
cancer cells in an ACSL3-dependent manner. Finally,
ACSL3 is essential for mutant KRAS lung cancer
tumorigenesis in vivo and is highly expressed in hu-
man lung cancer. Our data demonstrate that mutant
KRAS reprograms lipid homeostasis, establishing a
metabolic requirement that could be exploited for
therapeutic gain.
INTRODUCTION
Lung cancer remains one of the leading causes of cancer-related
death. Activating mutations of the proto-oncogene KRAS1614 Cell Reports 16, 1614–1628, August 9, 2016 ª 2016 The Author
This is an open access article under the CC BY-NC-ND license (http://(mutant KRAS) occur in 30% of the cases of non-small cell
lung cancer (NSCLC) (Cancer Genome Atlas Research Network,
2014; Pylayeva-Gupta et al., 2011). Continuous expression of
mutantKRAS is required for the survival of NSCLCboth inmouse
cancer models and human-derived NSCLC cells (Fisher et al.,
2001; Singh et al., 2009). Mutant KRAS promotes tumorigenesis
by regulating several oncogenic networks, for instance, the RAF/
MEK/ERK, PI3K/AKT/mTOR, and RHOA-focal adhesion kinase.
These observations establish mutant KRAS as a therapeutic
target. However, there are currently no approved therapies that
target tumors that harbor mutant KRAS (Gysin et al., 2011; Kon-
stantinidou et al., 2013; Pylayeva-Gupta et al., 2011).
Cancer cells undergo oncogene-directed metabolic reprog-
ramming to support cell growth and survival. For instance, can-
cer cells harboring mutant KRAS display a high level of carbon
flux through aerobic glycolysis and activation of glucose-depen-
dent biosynthetic pathways, including the synthesis of hexos-
amines and nucleotides (Boroughs and DeBerardinis, 2015; Hu
et al., 2012; Ying et al., 2012). Therefore, mutant KRAS drives
both the acquisition of nutrients and the orchestration of cellular
metabolism to convert carbon sources into biomass. However,
the relevance of metabolic reprogramming in tumorigenesis is
not completely understood.
The metabolism of fatty acids (FAs) is emerging as a mecha-
nism to cope with oncogenic stress. For instance, mutant
KRAS stimulates the cellular uptake of lysophospholipids, and
cancer cells with deregulatedmTORC1 are dependent on unsat-
urated FAs in hypoxic conditions (Kamphorst et al., 2013; Young
et al., 2013). Autophagy is also emerging as a mechanism to
maintain functional mitochondria, which are important for lipids.
creativecommons.org/licenses/by-nc-nd/4.0/).
metabolism (Guo et al., 2013). However, the mechanistic details
of the regulation and the biological significance of the cellular
metabolism of FAs in cancer cells are not completely
understood.
Fatty acids are fundamental cellular components that may be
used as building blocks for cellular membranes, as moieties for
post-translational protein modification, and as substrates for en-
ergy generation through b-oxidation. De novo FA synthesis in-
volves several key enzymes: ATP citrate lyase (ACL) generates
acetyl-coenzyme A (CoA) from citrate, which is typically pro-
duced in the mitochondrial tricarboxylic acid cycle (TCA) cycle;
acetyl-CoA carboxylase (ACC) catalyzes the irreversible carbox-
ylation of acetyl-CoA to form malonyl-CoA, the committed
metabolite in FA synthesis; and fatty acid synthase (FASN)
then sequentially adds 2-carbon units until a long-chain FA is
produced.
In most tissues, FASN expression is low; thus, most non-
transformed cells preferentially use dietary (exogenous) lipids
for energy generation and membrane maintenance (Menendez
and Lupu, 2007). However, proliferating cells avidly take up
free FAs from the environment and use them to generate phos-
pholipids, which constitute a substantial fraction of the dry
weight of mammalian cells (Deberardinis et al., 2006; Spector,
1967). Furthermore, overexpression of FASN occurs in several
human cancers, suggesting that some cancer cells and tumors
endogenously synthesize FAs (Furuta et al., 2008; Menendez
and Lupu, 2007).
Acyl-CoA synthetases (ACSLs) are a family of enzymes (i.e.,
ACSL1, 3, 4, 5, and 6) that convert free long-chain FAs into fatty
acyl-CoA esters, which then serve as a substrate for both lipid
synthesis and b-oxidation (Coleman et al., 2002). FAs are not
only de novo synthesized but also are taken from exogenous
sources. Once FAs are in the cell, ACSLs promote their retention
by converting them into hydrophilic fatty acyl-CoA esters that
cannot exit cells (Kamp and Hamilton, 2006).
ACSL enzymes utilize a wide range of saturated and unsatu-
rated FAs with a preference for FAs of chain lengths of 8–22;
however, they vary greatly in substrate specificity: for instance,
ACSL1 and ACSL5 prefer oleate, ACSL3 palmitate, and ACSL4
arachidonic acid (Grevengoed et al., 2014; Soupene and
Kuypers, 2008).
ACSL enzymes are ubiquitously expressed, even though indi-
vidual genes are differentially expressed in individual tissues and
differ in subcellular localization. For instance, ACSL3 is mainly
expressed in the endoplasmic reticulum (ER) and lipid droplets
and ACSL4 in peroxisomes and ER, whereas ACSL1, ACSL5,
and ACSL6 are expressed in mitochondria, plasma membrane,
and cytoplasm (Grevengoed et al., 2014; Soupene and Kuypers,
2008). Moreover, ACSL enzymes are expressed in pneumo-
cytes, where they participate in the synthesis of surfactant (Cole-
man et al., 2002; Schiller and Bensch, 1971).
ACSL enzymes also participate in the metabolic reprogram-
ming of cancer cells. For instance, pharmacologic inhibition of
ACSLs results in apoptosis in a subset of TP53-deficient cancer
cells (Mashima et al., 2005; Yamashita et al., 2000). Neverthe-
less, the biological significance of ACSL enzymes in promoting
tumorigenesis is still largely unknown. For instance, it remains
to be determined whether they play a role in the maintenanceof cancers expressing mutant KRAS. Furthermore, it is not
known whether glucose or fatty-acid-dependent cellular meta-
bolic processes are worthy of therapeutic targeting in KRAS
tumors.
In this manuscript, we show that ACSL3 is essential for the
oncogenic capacity of mutant KRAS in lung cancer. Our data
provide the rationale for the development of inhibitors that spe-
cifically target ACSL3 as anticancer drugs.
RESULTS
Mutant KRAS Regulates Glycolysis and Lipid
Biosynthetic Processes In Vivo
To gain insight into mutant KRAS-regulated cellular networks
that are required for tumor maintenance, we employed a trans-
genic mouse expressing a doxycycline (doxy)-inducible mutant
Kras transgene in the respiratory epithelium. For this purpose,
we crossed tetracycline operator-regulated KrasG12D (tet-op-
KrasG12D) mice with Clara cell secretory protein-tet activator
(CCSP-rtTA) mice. When fed with doxy, CCSP-rtTA/tet-op-
KrasG12Dmice invariably develop lung tumors, which are depen-
dent on continuous expression of KrasG12D (Fisher et al., 2001).
To obtain well-established lung tumors, we fed CCSP-rtTA/
tet-op-KrasG12D mice with doxy for 11 weeks. In agreement
with previous findings, withdrawal of doxy from the diet caused
KrasG12D extinction (Figure 1A; Fisher et al., 2001). Accordingly,
total RAS activity and activated PDK1, a well-known down-
stream target of KRAS, were also downregulated (Figures 1B
and 1C). Lung tumors completely regressed 6 days after doxy
withdrawal (Figure 1D).
To identify proximal molecular changes linked to KrasG12D
extinction, we performed whole-genome gene expression
analysis of micro-dissected lung tumors 24 or 48 hr after
doxy withdrawal. Database for Annotation, Visualization and
Integrated Discovery-based (DAVID) functional enrichment
analysis and gene set enrichment analysis (GSEA) between
experimental groups revealed a significant downregulation of
genes that regulate glycolysis and lipid metabolic processes
in mice undergoing KrasG12D withdrawal (Figures 1E–1G;
data not shown).
Mutant KrasG12D extinction significantly downregulates the
expression of the glycolytic enzymes hexokinase 2 (Hk2) and
lactate dehydrogenase-A (Ldh-A) in lung tumors in vivo (Fig-
ure 1H). This observation is consistent with the fact that mutant
KRAS has been associated with increased lactate production
in cancer cells in vitro (Yun et al., 2009). Furthermore, Hk2 and
Ldh-A play an important role in mutant Kras-driven lung tumori-
genesis (Patra et al., 2013; Xie et al., 2014). However, we found
that silencing of glycolytic enzymes decreases cell proliferation,
glucose consumption, and lactate production without causing
overall cell loss in vitro (Figures S1A–S1F).
Mutant KRAS Upregulates ACSL3 and ACSL4
We found that the lipid metabolic enzymes Acsl3 and Acsl4were
significantly downregulated in mouse lung tumors undergoing
KrasG12D extinction, whereas we did not detect significant
changes in mRNA levels of their family members Acsl1, Acsl5,
and Acsl6 (Figure 1I). Furthermore, KrasG12D lung tumors displayCell Reports 16, 1614–1628, August 9, 2016 1615
Figure 1. Mutant KRAS Regulates ACSL3 and ACSL4 in Lung Cancer Cells Both In Vitro and In Vivo
(A) Transgenic (KrasG12D) and endogenous (KrasWT) mRNA was quantified in micro-dissected lung tumors of CC10-rtTA/Tet-op-KrasG12Dmice by real-time PCR
at the indicated time points after doxy withdrawal.
(B) Pan-Ras activity was measured with an ELISA assay in micro-dissected lung tumors at the indicated time points after doxy withdrawal in CC10-rtTA/Tet-o-
KrasG12D mice; ***p < 0.0003.
(C) Immunoblot detection of P-Pdk1 in lysates of micro-dissected lung tumors at the indicated time points after KrasG12D extinction.
(D) H&E-stained lung tissue sections demonstrating lung tumor regression at the indicated time points after KrasG12D extinction; the scale bar represents 1 mm.
(E) Heatmaps of the genes found enriched in a genome-wide expression profiling, illustrating the changes in gene expression of the indicatedmetabolic pathways
24 hr upon doxy withdrawal. Expression level shown is representative of log2 values of each replicate from micro-dissected lung tumors (n = 4). Red signal
denotes higher expression relative to the mean expression level within the group, and blue signal denotes lower expression relative to the mean expression level
within the group.
(F) GSEA plot of glycolytic processes based on the 24-hr off-doxy versus on-doxy gene expression profiles. NES, normalized enrichment score; p, nominal value.
(G) GSEA plot of and lipid metabolic processes based on the 24-hr off-doxy versus on-doxy gene expression profiles.
(H) Real-time PCR showing mRNA levels of Hk2 and Ldh-A in lung tumors of KrasG12D mice before or 24 hr after KrasG12D extinction.
(I) Real-time PCR showingmRNA levels ofAcsl family members in lung tumors ofKrasG12Dmice before or 24–48 hr afterKrasG12D extinction. *p < 0.02; **p < 0.004.
(J) ACSL enzymatic activity in healthy lung parenchyma or in micro-dissected lung tumors after 11 weeks of KrasG12D induction or after the indicated length of
KrasG12D extinction. **p < 0.003; ***p < 0.001.
(K) ACSL enzymatic activity measured in BK fibroblasts treated with doxy for 24 hr.
(L) Real-time PCR showing mRNA levels of Acsl family members in BK fibroblasts treated with doxy for 24 hr.
(M) ACSL enzymatic activity in A549 NSCLC cells after transfection with the indicated siRNAs.
See also Figure S1.a striking upregulation of ACSL enzymatic activity compared to
lung tissue of non-transgenic littermates (Figure 1J). Conversely,
ACSL activity is downregulated by about 50% in lung tumors as1616 Cell Reports 16, 1614–1628, August 9, 2016early as 24 hr afterKrasG12D extinction (Figure 1J). These findings
suggest that ACSL enzymatic activity plays a significant role in
the maintenance of mutant KRAS lung cancer.
We tested whether Acsl3 and Acsl4 are dependent on
KrasG12D in cell culture with several complementary approaches.
We found that KrasG12D induction increases ACSL activity and
selectively upregulates Acsl3 and Acsl4 mRNA levels (Figures
1K, 1L, and S1G) in mouse embryonic fibroblasts derived from
tetracycline operator-regulated Tet-op-KrasG12D;p53/ trans-
genic mice (hereafter BK cells). These cells stably express
rtTA, allowing tight doxy-dependent expression of KrasG12D
(Pao et al., 2003).
Next, to demonstrate thatKrasG12D upregulatesAcsl3, we per-
formed transactivation assays in BK cells. We observed that
KrasG12D increases approximately by 3-fold the activity of an
ACSL3 promoter reporter (pGL3-ACSL3luc; Figure S1H; Cao
et al., 2010). Furthermore, treatment with rapamycin, a well-
known inhibitor of mTORC1, inhibits the ability of KRAS to
upregulate the ACSL3 promoter reporter (pGL3-ACSL3luc;
Figure S1I) and also Acsl3 mRNA (Figure S1J). These findings
suggest that mutant KRAS regulates ACSL3 expression through
the mTOR signaling pathway. In addition, KRAS silencing
reduces ACSL activity by about 50% in several NSCLC cells (Fig-
ure S1K and S1L). Finally, silencing of KRAS with a siRNA pool
significantly reduced ACSL3 mRNA levels (Figure S1M).
We silenced each of the ACSL family members (i.e., ACSL1,
ACSL3, ACSL4, ACSL5, and ACSL6) to determine their relative
contribution to ACSL cellular activity in mutant KRAS NSCLC
cells: knockdown of ACSL3 leads to the largest reduction of total
ACSL activity followed by the knockdown of ACSL4. However,
knockdown of ACSL1, ACSL5, and ACSL6 had modest to no
effect on total ACSL activity (Figures 1M and S1N).
Taken together, these results indicate that mutant KRAS
regulates ACSL activity both in vivo and in vitro and that
ACSL3 is the functionally predominant ACSL gene in mutant
KRAS NSCLC.
ACSL3 Is Required for the Survival of Mutant KRAS
In Vitro
In order to investigate whether ACSL3 promotes the survival
of lung cancer cells expressing mutant KRAS, we silenced
ACSL3 in a panel of human NSCLC cells, which have been
extensively characterized with respect to the presence of onco-
genic mutations (Sanger Institute Catalogue of Somatic Muta-
tions in Cancer and the Cancer Genome Atlas; Table S1).
ACSL3 silencing with two non-overlapping short hairpin RNAs
(shRNAs) striking reduced the proliferation of ten mutant KRAS
NSCLC cell lines and less-pronounced but still statistically signif-
icant inhibitory effects in the mutant KRAS HCC4017 and
HCC461 cells (Figures 2A, 2B, and S2A). TheseNSCLC cell lines,
with the exception of HCC461, carry also mutations inactivating
the TP53 and/or INK4A/ARF tumor suppressors. Notably,
ACSL3 silencing did not cause significant antiproliferative effects
in immortalized human bronchial epithelial cells (HBEC3KT cells)
that ectopically express mutant KRAS (Ramirez et al., 2004). In
contrast, the effect of ACSL3 silencing on cell viability was not
consistent in lung cancer cells carrying wild-type KRAS: we did
not detect significant adverse effects in six lung cancer cells
(H522, H596, H838, H1437, H2023, and HCC15) that harbor
wild-type KRAS but are mutant for either TP53 or INK4A/ARF
(Figures 2A and 2B). However,ACSL3 knockdown leads to inhib-itory effects in H125 (wild-type KRAS; TP53;INK4A/ARFmutant),
H661 (wild-type KRAS; TP53;INK4A/ARF mutant), and HCC95
(wild-type KRAS; TP53 mutant) lung cancer lines (Figure S2B).
In addition, there was no correlation between dependency on
ACSL3 and the proliferation rates of these NSCLC cells (Fig-
ure 2A; Table S1). Among the cell lines that were used for cell
proliferation assays, with exception for H1264, there was a pos-
itive correlation between ACSL3 abundance and sensitivity to
ACSL3 knockdown (Figures 2B and S2C).
To assess off-target effects, we performed rescue experi-
ments with retroviruses expressing ACSL3 cDNAs harboring
mutations ablating binding sites of either shRNA ACSL3 (A) or
shRNA ACSL3 (B), named ACSL3 mutant 1 and ACSL3 mutant
2, respectively (Figure 2C). The antiproliferative effect caused
by shRNA ACSL3 (A) was rescued by ACSL3 mutant 1, but not
by mutant 2 (Figure 2D). Conversely, the phenotype of shRNA
ASCL3 (B) was rescued by ACSL3 mutant 2, but not by mutant
1 (Figure 2D). As expected, cells expressing the shRNA-resistant
ACSL3 cDNAs had increased levels of ACSL3 as compared to
cells expressing wild-type ACSL3 cDNA (Figure S2D). Thus,
we conclude that the antiproliferative effects are specific to
ACSL3 knockdown and not due to off-target effects.
Next, we tested the effect of knocking down ACSL4, which is
also downregulated by mutant Kras extinction in lung tumors
(Figure 1I). However, knocking down ACSL4 both in mutant
and wild-type KRAS cells did not cause any significant effect
on cell proliferation (Figure S2E).
To begin assessing the mechanism underlying the depen-
dency on ACLS3, we assessed the effect of its silencing on
ACSL activity. We found that knockdown of ACSL3 reduced
ACSL activity by 55%–65% in mutant KRAS NSCLC cells but
only by 30%–35% in wild-type KRAS cells (Figure S2F). In addi-
tion, ACSL3 knockdown leads to the cell-line-dependent upre-
gulation of ACSL1, ACSL4, and ACSL6 in wild-type KRAS lung
cancer cells that are resistant to ACSL3 knockdown (Figures
S2G and S2H). In contrast, knockdown of ACSL4 reduced
ACSL activity only by 20%–30% in representative mutant
KRAS and wild-type KRAS NSCLC cells (Figures S2I and S2J).
Finally, we found that ACSL3 knockdown did not affect glucose
or glutamine consumption neither in mutant nor in wild-type
KRAS lung cancer cells (Figures S2K and S2L; data not shown).
Taken together, these results indicate that (1) mutant KRAS reg-
ulates ACSL activity both in vivo and in vitro, (2) ACSL3 is the
functionally predominant ACSL isoenzyme in mutant KRAS
lung cancer cells, (3) upregulation of otherACSL family members
and not glycolysis or glutaminolysis is likely to mediate the resis-
tance toACSL3 knockdown in wild-typeKRAS lung cancer cells,
and (4) the decrease of ACSL activity caused by ACSL4 knock-
down is below the threshold needed to cause detrimental effects
on cell viability.
Characterization of the Role of ACSL3 in Mutant KRAS
Lung Cancer Cells
ACSL3 silencing was accompanied by induction of apoptosis, as
shown by an increase in the percentage of the SubG0 population
of cells, cleaved poly (ADP-ribose) polymerase (PARP) and
cleaved caspase 3 in H460, H1264, and HCC44 cells, as repre-
sentative examples of ACSL3-dependent lung cancer cellsCell Reports 16, 1614–1628, August 9, 2016 1617
Figure 2. ACSL3 Is Required for the Proliferation of NSCLC Cells Expressing Mutant KRAS
(A) Growth curves of NSCLC cells upon transduction with the indicated shRNAs.KRAS status for each cell line is indicated. Doubling time ismentioned in hours in
parentheses.
(B) The histogram shows cell viability of the indicated NSCLC cells 96 hr after transfection with ACSL3 or control shRNAs.
(C) Schematic representation of the ACSL3 rescue cDNA mutants. shRNA recognition site and sequence of shRNA mutant 1 and 2 are indicated. Red letters
indicate mutated nucleotides.
(D) The histogram shows H460 (mutant KRAS) cell viability of lung cancer cell line transduced with retroviruses expressing the indicated shRNA and ACSL3
cDNAs.
See also Figure S2 and Table S1.
1618 Cell Reports 16, 1614–1628, August 9, 2016
Figure 3. ACSL3 Is Required for the Survival and Anchorage-Independent Growth of NSCLC Cells Expressing Mutant KRAS
(A) Flow cytometry showing the effect of shRNA-mediated ACSL3 knockdown on cell cycle of the indicated NSCLC lines. The percentages of cells in specific
phases of the cell cycle are indicated. Note the presence of cells in the sub-G0 phase of the cell cycle in the ACSL3-dependent H460 and H1264 cells, but not in
the ACSL3-independent H522 cells.
(B) Representative images of tissue culture plates showing soft agar colony formation assay in A549 and H460 (mutant KRAS) cells treated as indicated.
(C) Histograms showing quantification of colonies of A549 and H460 cells grown in soft agar upon transduction with the indicated shRNAs; ***p < 0.001.
See also Figure S3.(Figures 3A, S3A, and S3B). These changes were not evident in
H522 NSCLC cells, which are representative of the cells refrac-
tory to ACSL3 silencing (Figure 3A). In addition, we measured
mitochondrial membrane potential using JC-1 (5, 50, 6, 6’-
tetracholoro-1, 1’, 3, 30-tetraethylbenzimi-dazolylcarbocyanineiodide), a cytofluorimetric lipophilic cationic dye. Silencing of
ACSL3 leads to significant decrease in membrane potential in
H460 mutant KRAS cells (Figure S3C), which is consistent with
induction of apoptosis. Next, we assessed the effect of silencing
ACSL3 on mitochondrial respiratory activity. We found thatCell Reports 16, 1614–1628, August 9, 2016 1619
ACSL3 silencing significantly reduces basal oxygen consump-
tion rate (OCR) in real time in H460 mutant KRAS cells (Fig-
ure S3D). These results lend further support to the notion that
lung cancer cells that express mutant KRAS are vulnerable to
ACSL3 depletion.
To interrogate the functional significance of ACSL3 in KRAS
lung tumorigenesis, we performed colony formation assays in
soft agar and found that shRNA-mediated ACSL3 silencing re-
sults in more than 90% inhibition of colony formation in A549,
H460, and H1155, mutant KRAS NSCLC cells, but caused no
significant inhibition of colony formation in HCC15 and H2023
wild-type KRAS NSCLC cells (Figures 3B, 3C, S3E, and S3F).
These results indicate that ACSL3 is critical for maintaining the
ability of mutant KRAS NSCLC cells to grow in an anchorage-in-
dependent fashion, which is a hallmark of cancer cells (Hanahan
and Weinberg, 2011).
Taken together, these results support several conclusions: (1)
ACSL3 plays a critical role in promoting the survival of mutant
KRAS NSCLC cells; (2) silencing of ACSL3 does not lead to
generalized antiproliferative or proapoptotic effects, as demon-
strated by its inability to impair H522, H596, H838, H1437,
H2023, HCC15, and HBEC3KT cells; and (3) ACSL3 may exert
a prosurvival function in NSCLC cells carrying oncogenotypes
other than mutant KRAS, as demonstrated by the inhibitory ef-
fects we observed upon ACSL3 knockdown in H125, H661,
and HCC95 cells.
ACSL3 Promotes Fatty Acid Uptake, Accumulation of
Neutral Lipids, and b-Oxidation in Mutant KRAS NSCLC
Cells
Although mutant KRAS cancer cells display both de novo FA
synthesis and lipid uptake from extracellular sources, it is not
known which pathways predominate. It is also unknownwhether
mutant KRAS cells predominantly utilize these FAs as a sub-
strate for the synthesis of structural or storage lipids, for
instance, phospholipids or triacylglycerides (TAGs), and/or for
energy production by b-oxidation (Boroughs and DeBerardinis,
2015).
We observed that KrasG12D extinction in vivo leads to a time-
dependent (24–48 hr) downregulation of a set of genes known
to control FA entry into the mitochondria/peroxisomes or ER.
In particular, we detected genes responsible for long-chain FA
transport and FA oxidation (Figures 4A–4C, S4A, and S4B).
These observations suggest that KRAS enhances the expression
of genes involved in b-oxidation.
In order to gain insight into the impact of mutant KRAS on FA
uptake, synthesis of storage/structural lipids, and b-oxidation,
we employed isogenic BK cells. We found that mutant KRAS in-
creases the uptake of FAs from an exogenous source in BK cells
pulse labeled with the fluorescent FA BODIPY 500/510 C4,9,
which mimics a long-chain FA (BODIPY-FA) (Figures 4D and
4E; Kasurinen, 1992; Nchoutmboube et al., 2013). Conversely,
ACSL3 silencing significantly decreases the uptake and cellular
retention of fluorescent BODIPY-FA in NSCLC cells (Figures
4F, 4G, and S4C).
To better understand the role of mutant KRAS in cellular lipid
metabolism, we used a mass spectrometry method to measure
a lipidomic profile, including hundreds of TAGs, 250 phospho-1620 Cell Reports 16, 1614–1628, August 9, 2016lipids, cholesteryl esters, diacylglycerides, and free FAs (Fahy
et al., 2009; Mitsche et al., 2015). We found that induction of
mutant KRAS for 24 hr in BK cells increased TAGs and caused
an equivalent downregulation of lysophosphatidylcholine (LPC)
(Figures 4H and S4D; Table 1). This finding is consistent with
the observation that BODIPY-FA accumulates in structures
that resemble lipid droplets, the storage site for neutral lipids
(Figures 4D–4F and S4C).
Direct quantification of lipid classes indicates that the increase
in neutral lipids is accounted by an increase in diacylglycerides
(DAGs) and TAGs lipid species, which is consistent with the hy-
pothesis that LPCs are consumed in the synthesis of DAGs and
TAGs (Figures 4H and S4E). Conversely, ACSL3 knockdown de-
creases the intracellular content of TAGs (Figures 4I, S4E, and
S4F; Table 2). Figures S4G and S4H show a summary of the
composition of TAGs, phosphatidylcholines, and lysophosphati-
dylcholines with respect to their number of carbons and double
bonds in BK cells and in H460 prior and after doxy treatment or
ACSL3 knockdown, respectively.
In addition, knockdown of ACSL3 inhibits b-oxidation to a
degree similar to etomoxir, a known inhibitor of carnitine palmi-
toyltransferase, the rate-limiting enzyme that allows entry of
acyl-CoA FAs into the mitochondrion (Figure 4J; Pike et al.,
2011). Notably, knockdown of ACSL3 inhibits ATP production
to a degree similar to that of cells treated with etomoxir (Fig-
ure 4K). Importantly, etomoxir impairs cell viability in this context
(Figure 4L). Similarly, 4-bromocrotonic acid, an inhibitor of mito-
chondrial thiolase, a component of b-oxidation, reduces the cell
viability (Figure 4M).
These findings support the conclusion that ACSL3 in mutant
KRAS NSCLC critically regulates the uptake and cellular reten-
tion of long-chain fatty acyl-CoAs and their channeling to
b-oxidation for energy generation. Taken together, these data
suggest that inhibition of ACSL3 in vivo would have potent anti-
tumor effects.
ACSL3 Suppression Impairs Tumor Growth In Vivo
To gain insight into the significance of ACSL3 inhibition in vivo,
we performed xenograft experiments using A549 and H460
NSCLC cells, which are representative of our in vitro studies.
Silencing ACSL3 with shRNA(A), which we previously validated
to be specific, resulted in a remarkable suppression of tumor for-
mationwith 3.5-fold and 10-fold difference compared to the con-
trol A549 and H460 xenografts, respectively (Figures 5A and 5B).
Significantly, mice carrying xenografts with silenced ACSL3 had
also a dramatically increased survival (Figures 5C and 5D). These
results indicate that ACSL3 is required for the tumor growth
in vivo.
Loss of Acsl3 Results in Defective Tumorigenesis in
Mutant Kras Lung Cancer in Mice
We obtained mutant mice carrying a gene trap disrupting Acsl3
upstream of exon 1. Acsl3/ mice were characterized as null
based on the absence of transcripts by real-time PCR (LEXKO
011mouse strain; EuropeanMutant Mouse Archive; Figure S5A).
We confirmed the genotype of thesemice with a genotyping pro-
tocol that distinguishes between wild-type, heterozygous, and
homozygous littermates (Figure S5B).
Figure 4. Suppression of Fatty Acids Uptake and b-Oxidation upon Mutant KRAS Suppression
(A) Heatmaps illustrating the changes in expression of FA metabolism/b-oxidation genes 24 hr upon doxy withdrawal in mutant Kras lung cancer tumors in
transgenic mice. Expression level shown is representative of log2 values of each replicate frommicro-dissected lung tumors. Red signal, higher expression; blue
signal, lower expression relative to the mean expression level within the group.
(B) GSEA plot of FA metabolism/b-oxidation genes based on the 24-hr off-doxy versus on-doxy gene expression profiles.
(C) Real-time PCR showing the mRNA level of the indicated genes upon KrasG12D extinction in vivo; genes responsible for long-chain FA transport carnitine
O-octanoyltransferase (Crot) and fatty acid transporter-member 2 (Fatp2/Slc27a2) and 4 (Fatp4/Slc27a4); and genes that control FA b-oxidation, such as enoyl
coenzyme A hydratase (Echs1) and carnitine O-acetyltransferase (Crat); ns, statistically non-significant; *p < 0.01; **p < 0.003; ***p < 0.001.
(legend continued on next page)
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Table 1. Cellular Lipids Composition in BK Cells with KRAS
Induction
Lipid Classes BK Cells (%) BK Cells + Dox (%)
Endocyne 0.02 ± 0.0 0.02 ± 0.0
Lysophospholipids 7.48 ± 1.6 3.44 ± 1.5*
Neutral lipids 8.43 ± 1.1 11.38 ± 1.9**
Phospholipids 76.86 ± 6.3 78.24 ± 2.1
Polar lipids 7.20 ± 1.32 6.92 ± 1.5
Data shown are the mean ± SD of percentage of total lipids at a steady
state. Mutant KRAS was induced in BK cells by doxycycline (Dox) treat-
ment for 24 hr. *p < 0.05; **p < 0.001.
Table 2. Cellular Lipids Composition in H460 NSCLC Cells with
shRNA against ACSL3
Lipid Classes
Scrambled
shRNA (%)
shRNA
ACSL3(A) (%)
shRNA
ACSL3(B) (%)
Endocyne 0.02 ± 0.0 0.02 ± 0.0 0.02 ± 0.0
Lysophospholipids 6.76 ± 1.6 6.95 ± 0.8 7.46 ± 0.9
Neutral lipids 7.45 ± 1.1 5.58 ± 0.9* 6.00 ± 0.5*
Phospholipids 78.81 ± 6.3 81.08 ± 0.5 79.82 ± 0.9
Polar lipids 6.96 ± 1.3 6.36 ± 0.5 6.69 ± 0.5
Data shown are the mean ± SD of percentage of total lipids at a steady
state. *p < 0.05.We found that Acsl3/ mice are born according to the ex-
pected Mendelian ratio, without obvious macroscopic defects
during development or adult life. Histologically, lung tissue has
no morphological differences between the wild-type and
Acsl3/ littermates (Figure S5C). Considering that type II pneu-
mocytes and Clara cells are the probable precursor for lung tu-
mors (Sutherland et al., 2014; Xu et al., 2012), it is noteworthy
that there are no significant morphological differences between
wild-type and Acsl3/ littermates as confirmed with SP-C (sur-
factant-associated protein-C) and CCSP staining (Figure S5D).
Furthermore, RAS is present at comparable levels in the lungs
of wild-type and mutant littermates (Figure S5E). Nevertheless,
the lungs of Acsl3/ mice show about 40% decrease in ACSL
enzymatic activity as compared to their wild-type littermates
(Figure S5F). We conclude that, even though the loss of Acsl3
significantly decreases the ACSL activity in the lungs, the overall
morphology of the lungs is not affected.
To assess the role of Acsl3 in mutant Kras lung tumors in vivo,
we generated compound mutant mice by crossing LSL-
KrasG12D mice (LSL-Kras mice) with Acsl3 mutant mice, which
allows conditional expression of KrasG12D upon exposure to
Cre recombinase in the respiratory epithelium (Jackson et al.,
2001). We assessed lung tumorigenesis 8 weeks after intratra-
cheal delivery of an adenovirus that expresses Cre recombinase
(adeno-Cre). As expected, ACSL3 is undetectable in the lungs
of Ascl3/ mice and a pan-RAS antibody did not detect differ-
ences between KrasG12D;Acsl3 wild-type and KrasG12D;Acsl3/
mice (Figure S5G). We assessed tumor number and grade(D) BODIPY-FA uptake in BK cells treated with doxy as indicated. Red and
both cytoplasmic and membrane staining were considered positive); the scale b
BODIPY-FA.
(E) Fluorescence-activated cell sorting analysis of BK cells after a 30-min pulse
expressing mutant KRAS.
(F) BODIPY-FA retention in mutant KRAS HCC44 NSCLC cells expressing the i
negative cells, respectively; the scale bar represents 50 mm.
(G) The histogram shows the percentage of BODIPY-FA-positive HCC44 and H4
three separate areas).
(H) Composition of lysophosphatidylcholine (LPC) and triacylglycerides (TAGs) in
(I) Composition of LPC and TAGs in H460 NSCLC cells treated with the indicated
(J) b-oxidation assay in H460 NSCLC cells treated with the indicated ACSL3 shR
(K) Measurement of ATP in H460 NSCLC cells treated with the indicated ACSL3
(L) The histogram shows the viability of the indicated mutant KRAS NSCLC cells
(M) The histogram shows the viability of the indicated mutant KRAS NSCLC cells
See also Figure S4.
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Kras-driven lung cancer mouse models (DuPage et al., 2009;
Jackson et al., 2001). The overall tumor burden was significantly
decreased in LSL-KrasG12D;Acsl3/ mice as compared to
their LSL-KrasG12D;Acsl3+/+ littermates. As expected, in LSL-
KrasG12D;Acsl3+/+ mice, we detected adenomas with uniform
nuclei (A), atypical adenomatous hyperplasia (AAH), and bron-
chial hyperplasia (BH) (Figures 6A and 6B). In contrast, there
were no adenomas in the LSL-KrasG12D;Acsl3/ mice and all
lesions present were small areas of AAH or BH (Figures 6A
and 6B). We confirmed that the adenomas and AAH originated
from type II alveolar cells with SP-C staining (Figure 6C). In both
genotypes, there was equivalent activation of phospho-S6
(P-S6), which is one of the downstream targets of KRAS (Fig-
ure 6D). However, AAH lesions of KrasG12D;Acsl3/ mice had
decreased phospho-histone 3 (p-H3) as compared to the
ones of LSL-KrasG12D;Acsl3+/+ mice (Figures 6D and 6E). These
findings suggest that, even though Acsl3 loss does not affect
mutant KRAS signaling, it significantly impairs the capacity of
KrasG12D to promote cell proliferation and tumor initiation
in vivo.
ACSL3 in Human NSCLC
To determine whether ACSL3 has any significance in patients,
we assessed ACSL3 by immunohistochemistry (IHC) on a tissue
microarray (TMA) comprising 182 NSCLC patient samples. We
found low-level ACSL3 staining in type II pneumocytes of normal
lungs, whereas it is readily detectable in NSCLC specimenswhite arrows indicate positive and negative cells, respectively (cells with
ar represents 50 mm. Note that mutant KRAS induces the uptake/retention of
labeling with BODIPY-FA. Note uptake/retention of BODIPY-FA in BK cells
ndicated shRNAs. Red and white arrows indicate representative positive and
60 cells transduced with indicated ACSL3 shRNA (100 cells were counted in
BK cells with and without doxy treatment (*p < 0.05; **p < 0.001).
ACSL3 shRNA (*p < 0.05).
NAs or etomoxir; ***p < 0.001.
shRNAs or etomoxir.
72 hr after the indicated treatments; *p < 0.01; **p < 0.004.
72 hr after the treatment with 4-bromocrotonic acid; **p < 0.004.
Figure 5. ACSL3 Suppression Impairs
Tumorigenesis In Vivo
(A and B) Tumor volume of xenografts of A549 and
H460 NSCLC cells upon transduction with the
indicated shRNAs.
(C and D) Kaplan-Meier curves of nude mice car-
rying xenografts of A549 and H460 NSCLC cells
expressing the indicated shRNA upon trans-
duction with lentiviruses (n = 6/group).(Figure 6F). We used the Aperio Image Toolbox (Leica Bio-
systems) to quantify ACSL3 staining in lung cancer specimens
with a scoring scale, which takes into consideration the staining
intensity in conjunction with the percentage of positive cells
(H-score; ranging from 0 to 300). We considered an H-score of
less than 100, from 100 to 200, and above 201 having a low, in-
termediate, or high staining intensity, respectively. Overall, there
was a higher percentage of samples with the higher H-score of
>201 (Figure S5H). However, there was no significant difference
between the H-score of wild-type and mutant KRAS NSCLC
samples (Figure S5I). Notably, a significantly higher percentage
of surgical stage I (early stage) specimens displayed a higher
H-score as compared to stage III specimens (late stage; Figures
6G and S5J). We conclude that ACSL3 is highly expressed in
lung cancer. These results also suggest that ACSL3 may play
an important role in the early stages of tumorigenesis, a notion
that is consistent with our findings that ACSL3 is required for tu-
mor initiation in the LSL-KrasG12D mouse model of lung tumori-
genesis (Figures 6A and 6B).
DISCUSSION
The observation that extinction of mutant Kras in vivo causes a
prominent perturbation of the glycolytic and lipidmetabolic path-
ways in lung cancer cells suggests that these networks are
involved in lung cancer maintenance.
Glucose metabolism has been intensely studied in cancer cell
lines and tumors. Mutant KRAS induces aerobic glycolysis
in vitro and in vivo in mouse models of pancreatic and lung can-
cer (Racker et al., 1985; Ying et al., 2012). Furthermore, abroga-
tion of the glycolytic enzymes Hk2 and Ldh-A impairs without
abolishing the formation of mutant Kras lung tumors in mice (Pa-
tra et al., 2013; Xie et al., 2014). Our finding that suppression of
glycolytic enzymes reduces the proliferation of mutant KRASCell ReNSCLC cells without causing cell death
in cell culture is consistent with these
recent reports and suggests that alterna-
tive bioenergetic pathways, particularly
those that oxidize FAs, glutamine, or
other nutrients, may support the survival
of mutant KRAS lung cancer cells,
providing mechanisms that bypass the
inhibition of HK2, LHD-A, or other glyco-
lytic enzymes (Boroughs and DeBerardi-
nis, 2015).
We obtained several lines of evidence
that ACSL3 is the critical ACSL enzymerequired not only for the viability of mutant KRAS NSCLC cells
in culture but also for the ability of mutant Kras to promote tumor
initiation and progression in vivo. The observation that, in human
NSCLC specimens, ACSL3 is readily detected adds support to
the notion that ACSL3 plays a role in NSCLC tumorigenesis.
Longer follow-up will be needed to fully characterize the pheno-
type of Acsl3/ lung tumors, but taken together, our data
demonstrate that ASCL3 is a critical requirement for mutant
KRAS lung tumorigenesis.
Cancer cells display the ability to both synthetize FAs de novo
and to uptake them from extracellular sources (Boroughs and
DeBerardinis, 2015). We reason that the dependency on
ACSL3 is due to several properties of this enzyme. ACSL3 is
placed at a critical metabolic node because ACSL enzymes
are essential for both b-oxidation and lipid biosynthesis by acti-
vating long-chain FAs derived from either an exogenous or
endogenous source. Our observation that suppression of
ACSL3 leads to significant inhibition of b-oxidation with deple-
tion of cellular ATP, loss of mitochondrial function, and impaired
cell viability underscores the importance of this enzyme in
mutant KRAS lung cancer cells. Furthermore, we demonstrated
that mutant KRAS promotes the cellular accumulation of neutral
lipids (which are mostly by TAGs) in an ACSL3-dependent
manner. We speculate that lipid droplets, the organelles that
store neutral lipids, may provide substrates that support
b-oxidation in conditions of energetic stress, particularly in vivo.
Therefore, we conclude that ACSL3 is a critical non-redundant
therapeutic target for cancer types that rely on lipid metabolic
processes.
From a therapeutic point of view, it is also of interest that even
a partial decrease in ACSL enzymatic activity is sufficient to
achieve a critical therapeutic threshold without causing general-
ized toxicity in cultured cells or major phenotypes in Acsl3-null
mice. These observations suggest that ACSL3 is limiting inports 16, 1614–1628, August 9, 2016 1623
(legend on next page)
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conditions of oncogenic stress. Accordingly, inhibition of ACSL3
is likely to have a therapeutic window in vivo.
Moreover, ACSL3 is distal to FASN, where compensatory
mechanisms are less likely to occur (Coleman et al., 2002; Me-
nendez and Lupu, 2007). For instance, others have reported
that ACSL short-chain family member 2 (ACAS2) and FASN,
which are upstream of ACSL in de novo FA synthesis, may repre-
sent therapeutic targets (Hatzivassiliou et al., 2005; Menendez
and Lupu, 2007). However ACL and ACAS2 may compensate
for each other, whereas the requirement for FASN may be by-
passed by the uptake of exogenous lipids. In these regards,
our findings also provide a molecular explanation to the recent
observation that mutant KRAS promotes the scavenging of
longer-chain unsaturated FAs from lipids in the extracellular
space. In addition, these serum lipids are shown to promote
both proliferation and survival of Ras-driven human cancer cells
(Kamphorst et al., 2013; Salloum et al., 2014).
Our results suggest that the catalytic activity is required for
the vulnerability to ACSL3 depletion in mutant KRAS NSCLC.
However, we were unable to rescue the viability defect caused
by ACSL3 suppression with short-chain FAs that enter the mito-
chondrion in a CPT1A-independent manner. We reason that, in
addition to defective b-oxidation, several other processes could
contribute to the dependency of mutant KRAS lung cancer cells
on ACSL3. For instance, ACSL enzymes also provide substrates
for protein lipidation, such as farnesylation and myristoylation,
which are required for the activity of several oncogenes,
including KRAS (Gysin et al., 2011). It is also possible that these
important long-chain acyl-CoAs cannot be replenished by sup-
plementing medium-chain free FAs. Contrary to our expectation,
we did not detect changes in phospholipid content upon ACSL3
silencing; thus, we reason that it is not likely that a defect in the
synthesis of cellular membranes causes the loss of viability of
NSCLC cells, at least during the time frame of our experiments
(Yao and Ye, 2008). In principle, inhibition of ACSL3 could also
lead to the accumulation of cytotoxic free FAs; however, our
mass spectrometry data do not provide support to this hypoth-
esis. Future studies will be necessary to understand in greater
detail the mechanisms responsible for the dependency of
mutant KRAS lung cancer cells on ACSL3.
The results of our transactivation assays are consistent with
the notion that mutant KRAS regulates the ACSL3 promoterFigure 6. ACSL3 Is Required for the Initiation of KRAS-Driven NSCLC
(A) Images of KrasG12D lung cancers stained with H&E after 8 weeks of aden
adenomatous hyperplasia, and BH: bronchial hyperplasia (magnification: upper
(B) Histogram of tumor type distribution in mice with the indicated genotypes (*p <
indicated.
(C) Images of murine lung tumors stained with SP-C antibody. Positive staining
indicate the location of the inlets.
(D) Images of murine lung tumors stained with indicated antibodies. Antibody stain
indicate the location of inlets.
(E) The histogram shows the percentage of P-H3-positive cells in lung tumors of K
separate areas).
(F) Representative microphotographs of ACSL3 in the indicated representative
arrowhead indicates ACSL3 in type II pneumocytes. Arrows indicate the location
(G) Histogram showing H-score for ACSL3 staining intensity in tumor samples a
number of patient samples).
See also Figure S5.through mTORC1, which is a well-known regulator of the
SREBPs prolipogenic transcription factors, which in turn may
promote aberrant proliferation in cancer cells (Laplante and Sa-
batini, 2012). Furthermore, SREBPs are required for aberrant
proliferation and survival of breast cancer cells (Ricoult et al.,
2016). It is noteworthy that the ACSL3 and ACSL4, but not the
ACSL1 and ACSL6, promoters contain SREBP-binding sites.
Thus, it is likely that mutant KRAS regulates the ACSL3 promoter
through the mTORC1/SREBP pathway. It is also of interest that
wild-type KRAS NSCLC cells bypass the deleterious effects of
ACSL3 knockdown by upregulating other ACSL3 family mem-
bers. Thus, it will be of interest in the future to define in greater
detail themechanisms that regulate the expression of ACSL fam-
ily members.
Whereas we focused on NSCLCs with KRAS mutations, it is
likely that the detrimental effects on cell viability of ACSL3
knockdown are not restricted only to mutant KRAS lung cancer
cells, as demonstrated by the observation that H661, HCC95,
and H125 NSCLC cell lines with wild-type KRAS are also sensi-
tive to ACSL3 knockdown. The observation that a significant
percentage of lung tumors with high intensity of ACSL3 staining
does not carry mutant KRAS suggests that other oncogenic mu-
tations may upregulate ACSL3. Therefore, future studies will be
needed to determine the spectrum of lung cancer oncogeno-
types vulnerable to ACSL3 depletion.
Our report provides the important demonstration that mutant
KRAS positively regulates lipid metabolism, establishing a
requirement that can be exploited for therapeutic gain. We pro-
pose that ACSL3 is a target for the development of targeted ther-
apies against mutant KRAS lung cancer.EXPERIMENTAL PROCEDURES
All reagents and detailed methods are described in the Supplemental
Information.
Cell Lines, Reagents, and Plasmids
Human NSCLC cell lines and immortalized human bronchial epithelial
HBEC3KT cells (which ectopically express Cdk4 and hTERT) were from the
Hamon Center cell line repository (UT Southwestern Medical Center; Gazdar
et al., 2010; Ramirez et al., 2004). All cell lines were DNA fingerprinted for
provenance (PowerPlex 1.2 Kit; Promega) and were mycoplasma free
(e-Myco Kit; Boca Scientific). Fluorescent BODIPY-FA was from Molecularin Mice and Is Expressed in Patients
o-Cre infection. Lung nodules are indicated as A: adenoma, AAH: atypical
panels 12.53; bottom panels 1003).
0.05; ***p < 0.001; n, number of mice samples per genotype). Tumor types are
confirms their origin from type II alveolar cells (magnification 4003). Arrows
ing is in brown; nuclear counter staining is in blue (magnification 4003). Arrows
rasG12D; Acsl3+/+ and KrasG12D; Acsl/mice (100 cells were counted in three
human samples (respective H-score for tumor samples are indicated). Black
of inlet (the scale bar represents 200 mm).
ccording to their pathologic stages (*p < 0.05; ns, statistically insignificant; n,
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Probes, pBabePuro and pBabePuro-KRAS-G12V were from Addgene, the
ACSL3 cDNA was from Dr. Takahiro Fujino (Department of Bioscience, Ehime
University), and pGL3-ACSL3luc was from Dr. Jingwen Liu (Department of
Veterans Affairs Palo Alto Health Care System). We performed site-directed
mutagenesis using the Quickchange kit (Agilent). See also Supplemental Infor-
mation for tissue culture and assay conditions.
Mouse Studies
CCSP-rtTA/Tet-op-Kras (FVB/SV129 mixed background) mice were
described previously (Fisher et al., 2001). Acsl3/mice (LEXKO-011; Lexicon
Genetics) were obtained from the European Mouse Mutant Archive. We
generated LSL-KRasG12D;Ascl3/ mice with standard breeding techniques.
We performed xenograft studies as previously described (Konstantinidou
et al., 2013). For additional details, refer to the Supplemental Information.
Expression Profiling
Gene expression profiles were obtained from micro-dissected lung tumors of
19-week-old mice (Tusher et al., 2001). The data have been deposited in
NCBI’s GEO and are accessible through GEO: GSE40606. See also Supple-
mental Information.
RNAi
We obtained ACSL3 and ACSL4 or non-targeting small interfering RNAs
(siRNAs) (siGenome) and pLKO lentiviral vectors encoding shRNAs from
Thermo Scientific. siRNAs were transfected with DharmaFECT 4 Transfection
Reagent (Thermo Scientific). See also Supplemental Information.
Quantitative Real-Time PCR
We extracted RNAwith a RNA extraction kit (QIAGEN) and used Superscript III
(Invitrogen) to generate cDNA and SYBR Green PCR master mix (Applied Bio-
systems) for quantitative real-time PCR (qRT-PCR) analysis. See also Supple-
mental Information.
Immunoblotting and Antibodies
We performed immunoblots according to standard procedures (Konstantini-
dou et al., 2009). A list of the antibodies is provided in the Supplemental
Information.
Measurement of ACSL Activity and b-Oxidation
We measured ACSL activity in cell lysates by detecting incorporation of
radiolabeled palmitate into palmitoyl-CoA as previously described (Zhou
et al., 2007). We measured b-oxidation as described previously (Deberardinis
et al., 2006). See also Supplemental Information for details.
Flow Cytometry
We performed flow cytometry to detect the phases of the cell-cycle or
BODIPY-FA uptake according to standard procedures (Konstantinidou
et al., 2009; Nchoutmboube et al., 2013).
Lactate and Glucose Flux Measurements
Cell culture media was analyzed for glucose and lactate concentration using
a NOVA Biomedical Bio-Profile Basic 4 Analyzer, as described previously
(Yang et al., 2009).
Microscopy
For BODIPY-FA, immunofluorescent microscopy cells were fixed with 4%
formaldehyde in PBS for 20 min. We used Image J software to evaluate fluo-
rescence patterns and intensity (Schneider et al., 2012). For quantification,
we analyzed at least 100 cells in three independent fields. Cells positive for
BODIPY-FA staining both in the cytoplasm and cell membrane were consid-
ered positive.
Statistical Analysis
All data presented are the mean ± SEM or SD of experiments repeated three or
more times. We determined significance using two-tailed unpaired Student’s
t test or the one-way ANOVA test.1626 Cell Reports 16, 1614–1628, August 9, 2016ACCESSION NUMBERS
The accession number for the KRAS tumor microarray reported in this paper is
GEO: GSE40606.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.07.009.
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